Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1876494 | Applied Radiation and Isotopes | 2011 | 5 Pages |
Abstract
Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin's Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with 177Lu through a simple method. [177Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. Monte Carlo simulation showed high doses deposited on a spheroid tumor mass model. This method seems to be an appropriate alternative for the production of [177Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Paola F. Audicio, Gustavo Castellano, Marcos R. Tassano, Maria E. Rezzano, Marcelo Fernandez, Eloisa Riva, Ana Robles, Pablo Cabral, Henia Balter, Patricia Oliver,